MedicineAll countries · Checked
Liraglutide (Saxenda, Victoza): Weight Loss Use, Doses and Generics
Liraglutide is an injection you take once a day. Saxenda is the weight-loss brand and goes up to 3 mg, while Victoza is the same ingredient sold for type 2 diabetes. As of November 2026, both have generics in the US.
Liraglutide at a glance
One ingredient, two brands: Saxenda is for weight loss and Victoza is for type 2 diabetes.
Medicine and makerLiraglutide, Novo Nordisk
How you take itInjection, once a day
Saxenda dose range0.6 mg start, 3 mg maintenance
Victoza maximum1.8 mg
From the US labels.
Saxenda goes up every week for five weeks.
See the Saxenda weekly dose scheduleWant a cheaper version? See generic liraglutide.
LiraglutideSaxendaVictozaDoseResultsSide effectsMissed doseGenericPriceFAQ
Liraglutide
Liraglutide copies GLP-1, a gut hormone that helps control appetite and how full you feel.
Saxenda is for weight loss. Victoza is for type 2 diabetes. Two products carry the same ingredient, and each is approved for a different job.
In the US both come as a 3 mL pen of 6 mg/mL liquid, so each pen holds 18 mg.
There is no liraglutide pill. It is a daily injection only.
What is Saxenda?
Saxenda is the liraglutide injection approved for weight loss, used with a reduced-calorie diet and more physical activity.
In the US it is approved for adults with obesity, for teenagers aged 12 and over with obesity who weigh more than 60 kg, and for adults with overweight who have at least one weight-related condition.
In the EU the adult cutoff is a BMI of 30 or more, or 27 to under 30 with prediabetes, type 2 diabetes, high blood pressure, abnormal blood fats or sleep apnea. The EU label also covers children aged 6 to 11 with obesity who weigh at least 45 kg.
You can check your own number with the BMI calculator.
The EU authorized Saxenda on March 23, 2015.
Victoza and weight loss
Victoza is not a weight-loss medicine. The US label lists only blood sugar control in people aged 10 and over with type 2 diabetes, and lowering the risk of heart attack and stroke in adults with diabetes and heart disease.
The doses differ too. Victoza tops out at 1.8 mg a day, while Saxenda goes to 3 mg a day.
If weight loss is the goal, the approved choice is a weight-loss product. The two are not interchangeable just because the ingredient matches.
Saxenda dose
In the US you start at 0.6 mg a day and go up 0.6 mg each week, reaching 3 mg from week 5.
Week 10.6 mgWeek 31.8 mgWeek 5 on3 mg
For adults 3 mg a day is the recommended dose, and the lower doses are only steps on the way. If an adult cannot tolerate 3 mg, the label says to stop.
Teenagers aged 12 and over who cannot tolerate 3 mg may stay on 2.4 mg.
Adults should stop Saxenda if they have not lost at least 4% of their starting weight by week 16.
The full chart is in Saxenda dosing. You can inject at any time of day, with or without food.
Saxenda weight loss results
In the 56-week US trial of adults with obesity, or overweight plus a related condition, and no diabetes, average weight fell 7.4% on Saxenda and 3.0% on placebo.
No diabetes−7.4%Type 2 diabetes−5.4%Placebo, no diabetes−3.0%
Adults with type 2 diabetes lost 5.4% on average over 56 weeks, against 1.7% on placebo.
These are averages across everyone in the trial, and individual results vary a lot. For how other medicines compare, see GLP-1 drugs explained.
Liraglutide side effects
The most common side effects are stomach problems. This is how often adults in the US Saxenda trials reported them, next to placebo.
Saxenda vs placebo
Nausea39.3% vs 13.8%
Diarrhea20.9% vs 9.9%
Constipation19.4% vs 8.5%
Vomiting15.7% vs 3.9%
Injection site reaction13.9% vs 10.5%
The US label carries a boxed warning for thyroid C-cell tumors. It comes from studies in rats and mice, and it is not known whether the same happens in people.
Liraglutide is not used by anyone with a personal or family history of medullary thyroid cancer, or with MEN 2 syndrome.
Missed dose and half-life
The half-life is about 13 hours, which is why the injection is daily.
If you miss a day, take the next dose as scheduled. Do not double up to catch up.
In the US, if more than 3 days pass, the label restarts you at 0.6 mg and works back up the weekly steps.
Generic Saxenda and generic Victoza
In the US, Teva announced FDA approval and launch of a generic Saxenda on August 28, 2025. It is the first generic GLP-1 indicated for weight loss.
A Victoza generic came earlier. The FDA approved Hikma's generic Victoza on December 23, 2024.
In the UK, Biocon announced on February 28, 2025 the launch of Biolide for weight management and Liraglutide Biocon for diabetes.
In the EU, Ablymico was authorized on July 15, 2026 as a medicine based on Saxenda. More detail is in generic liraglutide.
Liraglutide price
Prices change by country, plan and pharmacy, so no figure is printed here. Use the GLP-1 price comparison for current numbers, or the cost tool to work out your own monthly spend.
Liraglutide FAQ
Are Saxenda and Victoza the same drug?
They share the ingredient, but they are not the same product. Saxenda is approved for weight loss and goes to 3 mg. Victoza is approved for diabetes and goes to 1.8 mg.
Is there a liraglutide pill?
No. Liraglutide only comes as a daily injection. A weight-loss pill is a different drug, such as the Wegovy pill.
Is Saxenda a weekly injection?
No. Saxenda is injected once a day. Weekly medicines such as Wegovy and Zepbound use other ingredients.
What is the maximum Saxenda dose?
3 mg a day. That is also the recommended dose for adults, and nothing higher is listed on the label.
Is there a generic Saxenda?
Yes. The US has a generic whose launch was announced on August 28, 2025, and the UK has Biolide.
Keep reading
Saxenda dosing: weekly step-up to 3 mg
Generic liraglutide: Saxenda and Victoza options
This page follows the official US and EU labels and is updated when a label changes. See how we check our pages.
Update log
: First published.
Sources
Saxenda US prescribing information (FDA, revised 02/2026).
Victoza US prescribing information (FDA).
Saxenda EPAR (European Medicines Agency).
Ablymico EPAR (European Medicines Agency).
Teva announcement of generic Saxenda (Teva).
FDA approves first generic of Victoza (FDA).
Biocon UK launch announcement (Biocon).
GLP1 Note is an independent information site. Your own treatment is decided by your prescriber.